H Roger Brown
Overview
Explore the profile of H Roger Brown including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
96
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brown H, Castellino S, Groseclose M, Elangbam C, Mellon-Kusibab K, Yoon L, et al.
Toxicol Pathol
. 2016 Jan;
44(1):112-31.
PMID: 26733602
Nevirapine (NVP) is associated with hepatotoxicity in 1-5% of patients. In rodent studies, NVP has been shown to cause hepatic enzyme induction, centrilobular hypertrophy, and skin rash in various rat...
2.
Suzuki A, Yuen N, Ilic K, Miller R, Reese M, Brown H, et al.
Regul Toxicol Pharmacol
. 2015 May;
72(3):481-90.
PMID: 25988394
Polypharmacy is common, and may modify mechanisms of drug-induced liver injury. We examined the effect of these drug-drug interactions on liver safety reports of four drugs highly associated with hepatotoxicity....
3.
Brown H, Mellon-Kusibab K, Bertram R, Tillman T, Arrington-Brown L, Jordan H, et al.
Toxicol Pathol
. 2013 Jul;
42(3):622-5.
PMID: 23867144
Previous reports investigating the mechanisms of galactosamine toxicity have discussed the presence of responders and nonresponders after intraperitoneal (IP) administration of a toxic dose. The incidence of nonresponders has been...
4.
Peterson R, Krull D, Brown H, de Serres M
Drug Metab Lett
. 2010 Jul;
4(3):180-4.
PMID: 20642451
Morphological evaluation of humanized chimeric mouse livers from the PhoenixBio (uPA(+/+)/SCID) mouse model show robust replacement and expansion with human hepatocytes, however areas of human hepatocytes had prominent steatosis and...
5.
Hoivik D, Qualls Jr C, Mirabile R, Cariello N, Kimbrough C, Colton H, et al.
Carcinogenesis
. 2004 May;
25(9):1757-69.
PMID: 15131011
There is little primate risk factor data in the literature evaluating the relationship between proposed mechanisms of PPAR agonist-induced hepatocarcinogenesis at clinically relevant therapeutic exposures. These studies were conducted to...
6.
Ringeissen S, Connor S, Brown H, Sweatman B, Hodson M, Kenny S, et al.
Biomarkers
. 2003 Aug;
8(3-4):240-71.
PMID: 12944176
This study identified two potential novel biomarkers of peroxisome proliferation in the rat. Three peroxisome proliferator-activated receptor (PPAR) ligands, chosen for their high selectivity towards the PPARalpha, -delta and -gamma...
7.
Brown H, Ni H, Benavides G, Yoon L, Hyder K, Giridhar J, et al.
Toxicol Pathol
. 2002 Aug;
30(4):452-69.
PMID: 12187937
As the genomes of mammalian species become sequenced and gene functions are ascribed, the use of differential gene expression (DGE) to evaluate organ function will become common in the experimental...
8.
Morgan K, Ni H, Brown H, Yoon L, Qualls Jr C, Crosby L, et al.
Toxicol Pathol
. 2002 Aug;
30(4):435-51.
PMID: 12187936
Large-scale analysis of gene expression using cDNA microarrays promises the rapid detection of the mode of toxicity for drugs and other chemicals. cDNA microarrays were used to examine chemically induced...
9.
Elangbam C, Brodie T, Brown H, Nold J, Raczniak T, Tyler R, et al.
Toxicol Pathol
. 2002 Aug;
30(4):420-6.
PMID: 12187934
We describe and discuss microscopic findings in the brown adipose tissue (BAT) blood vessels of Han Wistar rats treated with GI262570X, a peroxisome proliferator-activated receptor-gamma agonist (PPAR-gamma agonist) by oral...